ProCE Banner Activity

How I Use BTK Inhibitors to Treat My Patients With Waldenström Macroglobulinemia

Clinical Thought
Read this commentary from Prashant Kapoor, MD, on the use of BTK inhibitor therapy to treat patients with Waldenström macroglobulinemia.

Released: March 31, 2020

Expiration: March 30, 2021

Share

Faculty

Prashant Kapoor

Prashant Kapoor, MD

Assistant Professor of Medicine and Oncology
Consultant
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics AbbVie

Faculty Disclosure

Primary Author

Prashant Kapoor, MD

Assistant Professor of Medicine and Oncology
Consultant
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Prashant Kapoor, MD, has disclosed that he has received consulting fees from Cellectar, Karyopharm, Pharmacyclics, and Sanofi; funds for research from AbbVie, Amgen, GlaxoSmithKline, Sanofi, and Takeda; and fees for non-CME/CE services from Sanofi.